Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in alpha-tubulin.

Molecular cancer therapeutics - 1 Oct 2004

Loganzo Frank, Hari Malathi, Annable Tami, Tan Xingzhi, Morilla Daniel B, Musto Sylvia, Zask Arie, Kaplan Joshua, Minnick Albert A, May Michael K, Ayral-Kaloustian Semiramis, Poruchynsky Marianne S, Fojo Tito, Greenberger Lee M

Abstract excerpt

HTI-286, a synthetic analogue of hemiasterlin, depolymerizes microtubules and is proposed to bind at the Vinca peptide site in tubulin. It has excellent in vivo antitumor activity in human xenograft models, including tumors that express P-glycoprotein, and is in phase II clinical evaluation. To identify potential mechanisms of resistance induced by HTI-286, KB-3-1 epidermoid carcinoma cells were exposed to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ATP Binding Cassette Transporter, Subfamily G, Member 2
Share to Depsipeptides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Doxorubicin

Share to Mitoxantrone

Share to Multidrug Resistance-Associated Proteins

Share to Oligopeptides

Share to Sodium Azide

Share to Vinblastine

Source

Identifiers

PMID: 15486199

Genes

ABCG2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in alpha-tubulin.PMID 15486199Read ↗

Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha- or beta-tubulin and increased microtubule stability.Semantic proximity Read ↗

Microtubules: A dynamic target in cancer therapySemantic proximity Read ↗

Resistance to anti-tubulin agents: From vinca alkaloids to epothilonesSemantic proximity Read ↗

Resistance to microtubule-stabilizing drugs involves two events: beta-tubulin mutation in one allele followed by loss of the second allele.Semantic proximity Read ↗

Mechanisms of Resistance to CabazitaxelSemantic proximity Read ↗

Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization.Semantic proximity Read ↗

Microtubule alterations and resistance to tubulin-binding agents (Review)Semantic proximity Read ↗

A highly epothilone B-resistant A549 cell line with mutations in tubulin that confer drug dependence.Semantic proximity Read ↗

Induction of a multifactorial resistance phenotype by high paclitaxel selective pressure in a human ovarian carcinoma cell line.Semantic proximity Read ↗

Mutations in alpha- and beta-tubulin that stabilize microtubules and confer resistance to colcemid and vinblastine.Semantic proximity Read ↗

Effects of tubulin-inhibiting agents in human lung and breast cancer cell lines with different multidrug resistance phenotypes.Semantic proximity Read ↗

Human mutations that confer paclitaxel resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.